New Evidence Sheds Light on Stem Cell Transplantation for Progressive MS
Autologous hematopoietic stem cell transplantation (AHSCT) was not superior in preventing relapses or reducing disability progression than natalizumab (Tysabri) in progressive multiple sclerosis (MS), new research suggested. Patients with progressive MS, advanced disability, and low pre-treatment relapse activity who had AHSCT experienced similar on-treatment frequency of relapses as matched patients treated with natalizumab over up […]